INTRODUCTION
Parkinson's disease (PD) is the second most common degenerative disease, affecting 1 -2% of individuals older than 65 years. Clinical features of PD result primarily from the loss of dopaminergic neurons in the substantia nigra. Although the common form of PD is sporadic, six genes have been identified, mainly by linkage analyses of Mendelian forms of the disease. Two genes, SNCA (encoding a-synuclein) and LRRK2, have an autosomal dominant inheritance and four other genes, PARK2 (parkin), PARK6 (PINK1), PARK7 (DJ-I) and PARK13 (ATP13A2), have an autosomal recessive inheritance (1) . Frequently, mutations in these genes are found in patients with early-onset PD, particularly those with autosomal recessive inheritance. However, in most populations, Mendelian forms of parkinsonism are rare when compared with the most common form of PD, a frequent and complex disorder probably explained by the interaction between genetic and environmental factors.
The first two genome-wide association studies (GWASs) in PD (2, 3) provided evidence of association with several loci but most often not at the genome-wide significant level, and most initial association findings were not confirmed by subsequent replication analyses (4) . Two recent GWASs (5,6) reported strong or genome-wide significant associations with one or more of the known PD genes (i.e. SNCA, MAPT and/or LRRK2). So far, only two 'new' loci have been identified, 1q32/PARK16 and 4p15/BST1, in the Japanese data (5) . The US/UK/German GWAS (6) replicated positive association with variants at PARK16 but failed to replicate the association at BST1.
To identify additional variants that affect PD risk in the European population, we designed a three-stage GWAS of PD in three case -control samples from France, the UK and Australia (total of .13 300 subjects). A set of 50 top association signals was identified in the scan sample (1039 cases and 1984 controls from France) using the Illumina-610Quad chip. Promising and new signals were followed-up for stepwise replication in two further UK and French/Australian case -control studies (.3200 cases and 7000 controls).
RESULTS
The genome-wide association results from logistic test corrected for genomic inflation (GC) revealed two single nucleotide polymorphisms (SNPs) with P GC , 10 27 , and a substantial number of SNPs with strong (P GC , 10
24
) evidence of association ( Fig. 1 and Table 1 ). For practical reasons, we focus our attention on the 50 best-associated SNPs to prioritize for immediate in silico replication (Table 1) . Secondary logistic analyses, adjusted for the first two principal componenets (PCs) led to similar rank order of SNPs, albeit slightly weaker association signals (Table 1) . This suggests that the significant results, revealed by our primary analyses, are not biased by residual population substructure within our French scan sample. The 50 best-associated SNPs spanned 23 distinct genomic loci, and were associated with P GC , 5.6 × 10
25
. Sixteen associations were found within two well-known PD genes, i.e. SNCA (4q22, 4 SNPs) and MAPT (17q12 -q21, 11 SNPs), or within BST1 (4p15, one SNP), a recently reported PD risk locus established at the genome-wide significance level in a Japanese population (5 
. Association with the BST1 variant was also replicated but at a weaker significance level (OR ¼ 1.08, P ¼ 0.025). For all SNPs at SNCA, MAPT and BST1, the results in the French scan and the UK replication samples were highly congruent in terms of risk alleles and allele frequencies. As expected, ORs estimated in our scan study tend to be higher than those obtained in the replicationstage data, especially for BST1. Of the remaining 20 loci, association signals at three loci (four SNPs) were replicated with nominal P , 5% and with the same direction of effect. These SNPs were located on chromosomes 2q21.3 (rs621341, OR ¼ 1.08, P ¼ 0.028 and rs6723108, OR ¼ 1.11, P ¼ 0.005), 12p13.3 (rs11064524, OR ¼ 1.08, P ¼ 0.045) and 12q24 (rs4964469, OR ¼ 1.11, P ¼ 0.0045). Differences in allele frequencies across the data from France and UK were notable for the 2q21 -q22 SNPs. Indeed, the region encompasses the LCT (lactase) gene whose SNPs are known to vary in frequency across Europe, and rs6723108 has been shown to have different allele frequencies in the French and the UK -Irish populations (7).
We further followed-up the five replicated SNPs (from three newly identified loci and from BST1) in the second replication dataset (1527 cases and 1864 controls from France and Australia) ( Table 2 ). In stage 3, evidence of association was assessed with the Mantel -Haenszel test to control for the potential confounding owing to the different geographical origins (France versus Australia). Evidence of association was replicated for two SNPs located on 12q24 (rs4964469, OR ¼ 1.12, P ¼ 0.0175) and on 4p15/BST1 (rs4698412, OR ¼ 1.10, P ¼ 0.029). Association signals from joint analysis of the two replication datasets were improved for the same two SNPs only: at 4p15/BST1 (stage 2 + stage 3, P ¼ 0.0033) and at 12q24 (stage 2 + stage 3, P ¼ 0.00036) loci. Notably, joint analysis of the three datasets showed a consistently greater support for association for the newly identified locus on chromosome 12q24 (P ¼ 2.38 × 10
27
) than for 4p15/BST1 (P ¼ 1.79 × 10
26
). Additional analyses showed that our initial association signals were not confounded by age and they did not appear to be driven either by the subgroup of cases having an early age (,50) of onset of the disease or by those having a positive family history of PD (results not shown). The population-attributable risk (PAR) associated with SNCA, MAPT, BST1 and the 12q24 locus estimated in stage-1 data was 11, 20, 13 and 8%, respectively; in the combined data, PAR was 7% and 4% for BST1 and 12q24, respectively.
Finally, we also examined 18 SNPs from five loci, previously reported to be associated with PD at a genome-wide significance level from two published GWASs of PD (5,6) ( Table 3) . We added three SNPs (at SNCA and BST1) that were found strongly associated in our stage-1 data. The table also shows the results for a suggestive PD risk locus (GAK) reported by the published GWAS of PD from familial cases (8) . As for the previously reported PD loci, two loci only (SNCA and MAPT) have been identified with genome-wide significance at the screen stage: SNCA in both the Japanese and European populations and MAPT in the European population only. The two new PD risk loci (BST1 and PARK16) were identified in the Japanese population: association signals were strong (P , 10 26 ) in the discovery sample, and exceeded P , 10 28 in the combined data (5) . As already reported here, our GWAS provided genome-wide significance for two SNCA variants and replicated positive associations for variants at MAPT and BST1 loci. It is worth noting that allele frequencies may differ markedly between the Japanese and the European datasets, especially for SNPs at the SNCA and BST1 loci. Saliently, the directions of effects (i.e. risk allele) and effect sizes at SNCA variants are rather congruent across the European and Japanese datasets. For the remaining three PD loci, evidence of association was nominal (PARK16, P GC ¼ 0.03; LRKK2, P GC ¼ 0.04; GAK P GC ¼ 0.008) in the France-GWAS data.
DISCUSSION
Our genome-wide association analyses in the French scan data revealed two SNPs with genome-wide significance (P GC , 10
27
), and a number of additional SNPs with suggestive evidence (P GC , 10
24
). Here, we focused on the 50 top associated SNPs for immediate replication in two independent case -control samples. We used a stepwise replication design. To refine the set of most promising results, we first conducted in silico replication for the 50 SNPs in the WTCCC2 PD data (1705 cases and 5200 WTCCC controls). Replicated SNPs were genotyped and tested in a third dataset of 1527 cases and 1864 controls from France and Australia. Our scan stage showed genome-wide significance of association with PD for two SNPs at the 4q22/SNCA locus (P GC , 2.88 × 10
28
). Indeed, out of the 50 top associated SNPs, 15 are located in genomic regions of two known PD genes (SCNCA, MAPT) and one is located on 4p15/BST1, a risk locus recently reported with genome-wide significance in Japanese samples. SNPs at SNCA and MAPT were all significantly associated with PD in the UK-GWAS data (SNCA, P , 8 × 10
25
; MAPT, P , 2.75 × 10
26
). Evidence of association with 4p15/BST1 was also replicated in the UK sample but at a lower (rs4698412, P ¼ 0.025) significance level. Out of the remaining 34 SNPs, four SNPs (three loci) showed significant (P , 0.05) and consistent evidence of association in the UK data. A total of five SNPs (four loci: 2q21.3, 12p13.3, 12q24 and BST1) were followed-up for replication in the third case -control sample. Two of the four tested regions were replicated: 4p15/BST1 (P ¼ 0.03) and 12q24 The evidence of association (P GC , 1.35 × 10
25
, Tables 1  and 3 ) that we detected with several SNPs in the 3 ′ block of linkage disequilibrium (LD) of the SNCA locus ( Fig. 2A) , including the two SNPs reaching genome-wide significance in our scan sample, is highly consistent with previous PD GWAS studies (5, 6) .
MAPT is located in a large block of LD on chromosome 17q12 -q22, which contains several additional genes (Fig. 2B) . Previous studies (9,10) have identified a large haplotypic block associated with PD, with H1 and H2 being the at-risk and the protective haplotype, respectively. Our two most associated SNPs in the 17q12 -q22 region are located within this haplotypic block: rs17690703 (P GC ¼ 3.9 × 10
26
) and rs17563986 (P GC ¼ 1.3 × 10 25 ), the latter being at MAPT. In addition, H2 is tagged by the minor alleles of four of our genotyped SNPs: rs12185268/G, rs12373139/A, rs1981997/A and rs8070723/G. In our scan data, we found the same H1/H2 association signals, with all minor alleles of these four SNPs being significantly associated (P GC , 3.44 × 10
25
) with a decreased risk of PD ( Table 1) .
The BST1 gene has previously been associated with PD in a Japanese GWAS at a genome-wide significance level (5) . Strong evidence of association for rs4698412 was found in the Japanese scan (P ¼ 5.3 × 10
, OR ¼ 1.25) and in the combined (scan + replication) data (P ¼ 1.8 × 10
28
, OR ¼ 1.24) (5). A much weaker signal was obtained in the US/ UK/German data, in both the scan (P ¼ 0.09, OR ¼ 1.07) and the combined (P ¼ 0.03, OR ¼ 1.06) data (6) . Here, we report strong evidence of association of PD with BST1 (combined P ¼ 1.79 × 10
26
, OR ¼ 1.14). The most associated SNP (rs4698412) maps to a 15 kb LD-block (Fig. 2C) and is in high LD (r 2 ¼ 0.74/0.79) with the next top two BST1 variants (Table 3) . Despite the variation in the allele frequency of the risk allele between the Japanese (RAF ¼ 0.33) and the European (RAF ¼ 0.52-0.56) samples (Tables 2 and 3) , we found marked homogeneity in the direction of effects across the groups, but effect sizes seemed to be lower in European than in Japanese samples. BST1 has been proposed to play a role in generating cyclic ADP-ribose that serves as a second messenger for Ca 2+ mobilization in endoplasmic reticulum and thus Ca homeostasis-related BST1 could be a cause of selective vulnerability of dopaminergic neurons in PD (11) .
Our most associated SNP, on 12q24 (combined P ¼ 2.38 × 10
27
, OR ¼ 1.16), is 26 kb centromeric of RFX4 (Regulatory factor X4) (Fig. 2D) . Two other close genes, POLR3B (Polymerase RNA III polypeptide B) and RIC8B (Resistance to inhibitors of cholinesterase 8 homolog B), are 200 kb centromeric and telomeric of the 12q24 SNP, respectively. The RFX proteins belong to the winged-helix subfamily of helix -turn-helix transcription factors. The RFX4_v3 transcript variant is the only RFX4 isoform that is significantly expressed in the fetal and adult brain, and its expression is restricted to the brain. In addition, it has a role in the transcription of many genes involved in brain morphogenesis, such as the signaling components in the wnt, bone morphogenetic protein (BMP) and retinoic acid (RA) pathways. In particular, cx3cl1, a CX3C-type chemokine gene, which is highly expressed in brain in response to injury or infection and regulates intracellular calcium concentration, was downregulated Table 2 . GWAS and replication: loci considered to follow-up in RFX4_v3-null mice (12) . This allows speculation that RFX4 and BST1 are functionally linked and indirectly involved in the regulation of intracellular Ca 2+ concentrations, which plays an important role in various cellular functions and cell death. Finally, polymorphisms in RFX4 have been shown to be risk factors for the bipolar disorder, manic-depressive illness (13) . A recent study showed that a substantial proportion (10-15%) of top GWAS hits, so far identified, are e-quantitative trait loci (eQTLs), i.e. associated with gene expression levels (14) . We have initiated eQTL analysis using an existing brain expression database (15) , but so far failed to identify any association of the PD-associated rs4964469 SNP with the expression of known genes contained within the 12q24 region.
In conclusion, we have conducted a large GWAS of PD in three case -control samples from France, the UK and Australia. The GWAS stage has 75% and 33% power to detect the loci of the effect sizes observed in stage-1 data for the 12q24 variant (OR ¼ 1.27) at a significance of P , 5 × 10 25 and P , 10
, respectively. In the scan-step, we detected genome-wide significance of association with PD for two SNPs on 4q22, and strong evidence of association with 17q12 -q22 SNPs. The two regions encompass previously reported loci: SNCA and MAPT, respectively. Human
In addition, we confirmed, for the first time in subjects of European ancestry, the association of PD with 4p15/BST1, recently identified in Japanese samples. Finally, we identified a new locus on 12q24, potentially associated with PD. Further replication studies conducted in large casecontrol samples are warranted to evaluate the contribution of this locus to PD risk.
MATERIALS AND METHODS

Sample ascertainment and diagnostic criteria
The main characteristics of the three case-control samples are shown in Table 4 .
Stage-1 subjects. The total number of cases and controls from France included in stage 1 was 1070 and 2023 controls, respectively. † PD subjects: Patients were recruited through the French network for the study of Parkinson's disease Genetics (PDG) that comprises 15 university hospitals across France. Definite and probable PD was defined according to standard criteria. Definite PD required at least two of three cardinal signs (akinesia and/or rigidity and/or tremor) and absence of exclusion criteria (ophthalmoplegia, pyramidal or cerebellar signs, early dementia, urinary incontinence or postural instability and prior exposure to neuroleptic drugs), and a positive and sustained response to levodopa therapy. Probable PD required at least two of the five following criteria: the parkinsonian triad, a good response to levodopa therapy and asymmetrical onset. Most (.80%) of the PD cases fulfilled the criteria for definite PD. Patients were selected in an effort to enrich for individuals who may have greater genetic predisposition to PD, through selection of cases with a positive family history of PD (Table 4) . Cases were of European origin, mostly French (n ¼ 930). Subjects diagnosed genetically with known PARK mutations (SNCA, LRRK2, parkin and PINK1) were excluded. (16) . Participants (.9000) are non-institutionalized subjects, over 65 years of age, randomly selected from the electoral rolls of each city. Patients with Alzheimer's disease or other types of dementia, and individuals for whom information on their dementia status during the 4-year follow-up was missing were further excluded. Here, we used a sample of 2023 neurologically normal subjects matched on gender with PD cases, randomly selected from all the participants.
Stage-2 subjects. In silico replication sample: we exchanged genome-wide association data with the WTCCC2 PD study group (Spencer et al., submitted). This case -control study consisted of 1705 PD cases and 5200 controls from the 1958 Birth Cohort and from the OK Blood Services Controls (17).
Stage-3 subjects. De novo genotyping was conducted in two independent case -control datasets from France (872 PD, 1440 controls) and Australia (655 PD, 424 controls). The subjects from France were combined from three French studies: TERRE (207 cases, 468 controls), PARTAGE (313 cases, 593 controls) and an extension of PDG (352 cases, 378 controls). The extension PDG study includes patients who were not available at the time of the stage-1 genotyping execution and neurologically normal spouses of PDG patients. In cases, the mean age at examination and the mean age of onset of PD is 59 (30-86) and 50 (20 -84) years, respectively. The mean age of controls is 60 (31 -85) years. In PARTAGE, patients and controls were identified among affiliates of the Mutualité Sociale Agricole (MSA) from five French districts. Parkinsonism was defined as the presence of at least two cardinal signs (rest tremor, bradykinesia, rigidity, impaired postural reflexes); PD was defined as the presence of parkinsonism after exclusion of other causes of parkinsonism. Controls were randomly selected from all MSA affiliates in the same districts and matched for sex and age (+2 years). DNA was collected from saliva (Oragene kit). Cases and controls have a mean age of 67 (37 -79) years, and the mean age of onset of disease is 63 (35 -75) years. TERRE is based on a similar protocol (18) , but DNA was collected from blood; the mean age in cases and controls is 73 (46 -82) years, and the mean age of onset is 66 (39 -80) years in cases.
Australian study: Subjects with PD were recruited from one private and two public movement disorder clinics in Brisbane. Controls were electoral roll volunteers and patient spouses, excluding the subjects demonstrating signs of parkinsonism (19) . The mean age is 72 (34 -105) and 74 (33 -107) years in controls and cases, respectively; the mean age of onset is 59 (23 -96) years in cases. Only Caucasian subjects were included in stage 3; in the Australian study, analyses were restricted to participants who reported having four European grandparents (.85% British). There was no overlap between the subjects used in the replication datasets and those included in the stage-1 data. Written informed consent was obtained for all participating subjects and research protocols were approved by local ethics committees.
Genotyping
Stage-1 genotyping. DNA samples of PDG cases and 3C controls were transferred to the French Centre National de Géno-typage. First-stage samples that passed DNA quality control (QC) (1064 PD cases and 2023 controls) were genotyped with Illumina Human610-Quad BeadChip and subjected to standard QC procedures. Stage-3 genotyping. Genotyping in the extended PDG sample was carried out in the UMR/S 975 laboratory, using predesigned TaqMan probes (C_537709_10/ rs621341; C_29330880_10/ rs6723108; C_12096605_10/ rs11064524; C_2775670_10/ rs4964469; C_1216796_10/ rs4698412) on an ABI 7500 Real-Time PCR system Applied Biosystems, Foster City, CA, USA), according to the manufacturer's instructions. Data were then analyzed using the 7500 software v.2.0.1. The TERRE/PARTAGE and Australian samples were genotyped using the Sequenom MassARRAY platform, with the iPLEX protocol (Genoscreen, France). The basic protocol involves a multiplex primer extension followed by matrixassisted laser desorption ionization-time of flight mass spectroscopy detection. In order to avoid any genotyping bias, cases and controls were randomly mixed when genotyping and, laboratory personnel were blinded to case-control status.
Quality control of France GWAS scan data
Various stringent QC filters were applied to remove poorly performing SNPs and samples using tools implemented in PLINK version 1.7 (20) . SNP QC: Markers were removed if they had a genotype-missing rate .0.03 or a minor allele frequency (MAF) , 0.05 or a Hardy -Weinberg P ≤ 10
25 . This SNP QC step led to the removal of 74 660 autosomal SNPs. Thus, subsequent analyses were based on 492 929 SNPs.
Individual QC: Samples were removed based on standard exclusion criteria: call rate of ,96% (22 subjects), inconsistencies between reported gender and genotype-determined gender (11 subjects) and genetic relatedness (identity-by-descent estimate .0.14; 6 subjects). Applying these QC filters led to the removal of 39 subjects (14 cases, 25 controls).
Population stratification and principal component analysis: To detect individuals of non-European ancestry, we thinned the SNPs to reduce LD to a set of 55 193 SNPs. To this end, we removed SNPs from the extensive regions of LD (CHR2, CHR5, CHR6, CHR8, CHR11) (21) , and excluded SNPs if any pair within a 1000-SNP window had r 2 . 0.2. Our stage-1 genotype data were then merged with genotypes at the same SNPs from 381 unrelated European (CEU), Yoruban (YRI) and Asian (CHB and JPT) samples from the HapMap project. Principal component analysis was applied using EIGENSTRAT (22) . The two PCs clearly separated the HapMap data into three distinct clusters according to ancestry, and most of our stage-1 samples were clustered with the HapMap European samples (Fig. 3) . Thirty-two samples appeared to be ethnic outliers (including one subject clearly sharing African ancestry) from the European cluster and were excluded from further analysis. The final post-QC scan sample comprised 1039 PD cases and 1984 controls.
Statistical analysis
Association analysis of the genotype data was conducted with PLINK (20) .
Stage-1 association analyses. Logistic regression was used to study the allelic association between each SNP and PD assuming an additive genetic model. Our analysis was based on 492 929 SNPs, and on a conservative genome-wide significance threshold of 0.05/492 929 ¼ 10
27
. The distribution of the association results was found to be marginally inflated (median x 2 ¼ 0.521); genomic inflation factor l ¼ 1.14 (l 1000 ¼ 1.10). Logistic regression analysis adjusted for the two first PCs of the EIGENSTRAT analysis revealed a genomic inflation of 1.03 (median x 2 ¼ 0.472). As for our primary analyses, we applied the genomic inflation correction method (23) ; the median of the GC-corrected x 2 value was 0.447.
Sensitivity analyses: Two further analyses were conducted to assist in the interpretation of results of the identified GWAS SNPs. We performed age-adjusted regression analysis and conducted subgroup analyses of two subtypes of cases against all controls. Cases with a disease onset before 50 years (n ¼ 428) were classified as 'early AOO', and cases 
